Interestingly, sequencing of cancer genomes revealed recurrent gain-of-function mutations in genes encoding key positive regulators of NF-κB signaling and inactivating genetic aberrations in negative regulators of this pathway. This evidence concerns the gene NFKB1 and cancer.